Holly Philpot
Nurse Practitioner · Athens, GANPI 1386868768
Payments from drug & device makers
Across 516 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- EMD Serono, Inc.$760
- UCB, Inc.$759
- TG Therapeutics, Inc.$677
- Eisai Inc.$319
- Novartis$319
- plus $4K from 46 others
What the payments were for
- Food & beverage$8,474100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$124
How this compares
$8,508 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 96 | $111,820 |
| BetaseronInterferon Beta-1b | 11 | $104,873 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $74,998 |
| Emgality PenGalcanezumab-Gnlm | 86 | $66,237 |
| QuliptaAtogepant | 45 | $48,286 |
| Nurtec OdtRimegepant Sulfate | 28 | $45,490 |
| BriviactBrivaracetam | 22 | $32,143 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $29,600 |
| Dalfampridine ErDalfampridine | 43 | $17,312 |
| Memantine Hcl | 466 | $17,132 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 13 | $15,229 |
| EliquisApixaban | 13 | $7,613 |
| Levetiracetam | 157 | $4,698 |
| Gabapentin | 291 | $4,408 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 202 | $3,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $1,567 | $160,107141 claims |
| PfizerOctagam, Nurtec Odt, Eliquis | $212 | $128,10254 claims |
| UCB, Inc.Briviact | $759 | $32,14322 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $1,53470 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.
Other nurse practitioner in Athens
- Sue PhelpsAthens$14K
- Andrea MealorAthens$10K
- Crystal LogsdonSavannah$566K
- Victor CzerkasijDalton$505K
- Kennon Mc CollumStockbridge$364K
- Pamela AllenRome$270K
- Tajuana BradleyJohns Creek$256K
- Janice McAlisterAtlanta$241K
- Jessica AdkinsSavannah$226K
- Laura ElledgeAtlanta$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.